Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.

ABSTRACT:

SUBMITTER: Coleman RL 

PROVIDER: S-EPMC5901715 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature